Safety Profile

Quick Answer

A safety profile brings together information about a medicine’s adverse effects and risks, the people and circumstances studied, and the limits of that evidence. Prescribing information organizes much of this information into warnings, contraindications, adverse reactions, interactions and population-specific sections. An adverse event observed during a study is not automatically an effect caused by the medicine. (FDA labeling guide; FDA safety-reporting terminology)

Evidence basis: High for the cited regulatory definitions and documented label contents. This describes confidence in those source statements, not a medicine’s safety or effectiveness.

Adverse Events, Reactions and Seriousness

• Adverse event: An unfavorable medical occurrence associated with use of a medicine, whether or not it is considered related to that medicine.
• Suspected adverse reaction: In FDA investigational-drug reporting, evidence suggests a possible causal relationship.
• Adverse reaction in prescribing information: An undesirable effect reasonably associated with the medicine, with some basis for a causal relationship.

These terms describe different evidentiary judgments; a list of reported events should not be presented as a list of proven drug effects. (FDA IND definitions; FDA labeling guide, Table C footnote 2)

Severity and seriousness are different. Severity describes intensity. Seriousness concerns outcomes or consequences such as death, hospitalization or persistent disability, and can also include medically important events requiring intervention. A severe symptom is not automatically a serious event under reporting definitions. (FDA/ICH E2A, section II.B)

Reading the Safety Sections of a Label

Section	What it addresses
Boxed warning, when present	Risks or contraindications requiring prominent emphasis
Contraindications	Circumstances in which the medicine must not be used
Warnings and precautions	Clinically significant risks and relevant precautions
Adverse reactions	Reaction information from studies and postmarketing reports
Drug interactions	Clinically significant interactions
Use in specific populations	Information relevant to groups such as children, older adults and people with renal impairment

The sections applicable to a product depend on that product’s evidence and labeling. (FDA guide to prescribing information, Table C)

Warnings Are Product Specific

GLP-1 medicines should not be assigned one universal thyroid boxed warning. The U.S. Bydureon BCISE label, revised May 2025, contains a boxed warning about thyroid C-cell tumors observed in rats and states that the relevance to humans is unknown. The Byetta label, revised September 2025, has no boxed warning. Both contain exenatide, but they are different formulations with different labeling. (Bydureon BCISE boxed warning; Byetta prescribing information)

This difference does not establish that one product is risk-free or safer overall. The complete label, including its other warnings, still matters; the boxed-warning comparison alone cannot answer that question.

Interpreting Adverse-Event Percentages

A percentage needs its study context: the product and formulation, population, comparator, follow-up period, number of participants and event definition. A range assembled across unrelated studies can obscure those differences. Byetta’s prescribing information explicitly cautions against direct comparison of adverse-reaction rates from different drugs’ trials. (Byetta, section 6.1)

Subtracting two reported percentages gives a percentage-point difference. That arithmetic alone does not demonstrate that the medicine caused every excess event or establish an individual’s risk. FDA’s safety-reporting framework requires assessment of causal evidence, which can include comparisons with a control group. (FDA safety-reporting requirements)

For peptide-specific context, consult the evidence dossiers for semaglutide, tirzepatide and liraglutide, including their stated populations and limitations.

Postmarketing Evidence Has Limits

The FDA’s Adverse Event Monitoring System (AEMS) public dashboard, formerly FAERS, makes reported events available for review. FDA cautions that these reports can be incomplete or duplicated, do not establish causation and cannot by themselves estimate how frequently an event occurs. Raw report counts are therefore not a reliable ranking of medicines’ safety. (FDA AEMS dashboard limitations)

When reading an updated safety summary, distinguish a new report from an assessed safety signal or a change to the product’s labeling. The label’s revision date is also not necessarily the date of a major new safety finding: FDA notes that revisions can be substantial or minor. (FDA labeling guide)

Pregnancy and Other Populations

Safety information is product- and population-specific. A general statement about older adults, pregnancy or renal impairment cannot replace the relevant label section.

FDA removed the A, B, C, D and X pregnancy letters from prescription labeling under its Pregnancy and Lactation Labeling Rule. The current approach uses more detailed information; the rule does not change OTC labeling. The old letters should not be used as a current risk-ranking system. (FDA pregnancy-labeling questions 3-4)

Frequently Asked Questions

Does an adverse-event report prove the medicine caused it?

No. FDA distinguishes a reported event from evidence supporting a causal relationship. Spontaneous reports alone do not establish causation or incidence. (FDA AEMS limitations)

Can I compare two products using a single side-effect percentage?

A percentage alone is insufficient. Check the study population, comparator, product and follow-up, and avoid treating rates from separate trials as a direct comparison. (Byetta, section 6.1)

Does a safety profile tell me which treatment to choose?

This glossary explains evidence and labeling terminology. It does not assess an individual’s suitability for treatment; that requires discussion with a qualified healthcare professional.

Educational information only. This entry is not medical advice.

Sources

Sources checked September 29, 2026. Product examples refer to U.S. labeling.

1. FDA: Frequently Asked Questions about Labeling for Prescription Medicines.
2. FDA: IND Application Reporting — IND Safety Reports.
3. FDA/ICH E2A: Clinical Safety Data Management, section II.B.
4. Byetta prescribing information, revised September 2025, hosted by NLM DailyMed.
5. Bydureon BCISE prescribing information, revised May 2025, hosted by NLM DailyMed.
6. FDA: AEMS Public Dashboard and data limitations.
7. FDA: Questions and Answers on the Pregnancy and Lactation Labeling Rule.